Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management and risk mitigation strategies for FLT3-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.

Leukemia & lymphoma - 1 Aug 2026

Horsch Laurie, Baron Jeffrey, Sung Pamela J, Wang Eunice S

Abstract excerpt

Acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations represent a clinically aggressive subtype of AML characterized by a poor prognosis and high frequency of relapse. Although several FLT3 inhibitors exist, they differ in their side effects, potency and clinical use. Quizartinib is a potent next generation FLT3 inhibitor with a risk of QTc-prolongation necessitating a Risk Evaluation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to FLT3 gene

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tandem Repeat Sequences

Share to Treatment Outcome

Source

Identifiers

PMID: 42217224
DOI: 10.1080/10428194.2026.2676107

Genes

FLT3
CYP3A4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management and risk mitigation strategies for FLT3-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.PMID 42217224Read ↗

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.Semantic proximity Read ↗

Quizartinib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.Semantic proximity Read ↗

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.Semantic proximity Read ↗

The role of quizartinib in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.Semantic proximity Read ↗

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.Semantic proximity Read ↗

[Current status and challenges of AML treatment with FLT3 inhibitors].Semantic proximity Read ↗

Safety of FLT3 inhibitors in patients with acute myeloid leukemia.Semantic proximity Read ↗

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity Read ↗

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.Semantic proximity Read ↗

The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.